Entrar/Registro  
INICIO ENGLISH
 
Revista Alergia México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Alergia México >Año 2009, No. 4


Rubio-Padilla M, Río-Navarro BE, Hilda SN, Sienra-Monge JJL
Asma de difícil control. Revisión de la bibliografía
Revista Alergia México 2009; 56 (4)

Idioma: Español
Referencias bibliográficas: 34
Paginas: 115-123
Archivo PDF: 748.10 Kb.


Texto completo




RESUMEN

El asma de difícil control es una enfermedad que causa ataques graves, que amenazan la vida, provoca hospitalizaciones frecuentes y requiere la prescripción de corticoesteroides. Los factores de riesgo para asma grave son: sexo femenino, IMC elevado, sensibilidad a la aspirina, reflujo gastroesofágico, sinusitis, antecedente de neumonía e inicio de los síntomas de asma en adultos mayores. En pacientes con asma grave, se ha demostrado cambio en el perfil inflamatorio, con mayor participación de neutrófilos y evidencia de destrucción y remodelación. El primer paso en el cuidado de estos pacientes es la evaluación adecuada para establecer el tipo correcto de asma. Una evaluación sistemática y rigurosa ayuda en la valoración adecuada del diagnóstico diferencial, las comorbilidades asociadas y los factores desencadenantes inusuales. El objetivo del tratamiento es conseguir los mejores resultados, con los mínimos efectos indeseables. Se necesitan nuevas terapias inmunomoduladoras para tratar a estos pacientes.


Palabras clave: asma, asma grave, control.


REFERENCIAS

  1. Strek M. Difficult asthma. Proc Am Thorac Soc 2006;3:116-23.

  2. Chung K, Godard P, Adelroth E, Ayres J, et al. Difficult/therapy resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. Eur Respir J 1999;13:1198-208.

  3. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000;162:2341-51.

  4. Wenzel SE, Busse WW, National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21.

  5. López-Viña A, Agüero-Balbín R, Aller-Álvarez JL, Bazús- González T, et al. Normativa para el asma de control difícil. Arch Bronconeumol 2005;41(9):513-23.

  6. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, et al. Severe asthma in adults: whay are the important questions? J Allergy Clin Immunol 2007;119:1337-48.

  7. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Resp Rev 1998;8:348-50.

  8. Dolan CM, Fraher KE, Bleecker ER, Borish L, et al, Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study- a large cohort of patients with severe or difficult to treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39.

  9. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13.

  10. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470-7.

  11. Fitzpatrick AM, Gaston B, Erzurum S, Teague W. Features of severe asthma in school age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006;118:1218-25.

  12. Chipps BE, Szefler SJ, Simons ER, Haselkorn T, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007;119:1156-63.

  13. Jatakanon AN, Uasuf CA, Maziak WA, Lim SA, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.

  14. Hamilton L, Torres-Lozano C, Puddicombe SM, Ritcher A, et al. Role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy 2003;33:1-8.

  15. Holgate ST, Polosa R. The mechanisms, diagnosis and management of severe asthma in adults. Lancet 2006;368:780-93.

  16. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360-8.

  17. Brasier AR, Victor S, Boetticher G, Ju H, et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008;121:30-37.

  18. Plaza-Moral V, Álvarez-Gutiérrez FJ, Casan-Clarà P, Cobos-Barroso N, et al, Guía Española para el Manejo del Asma (GEMA). Arch Bronconeumol 2003;39:S1-42.

  19. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference. Summary of recommendations. Can Respir J 1996;3:89-100.

  20. Dewey A, Bara A, Dean T, Walters EH. Dapsone as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2002;(3):CD003268.

  21. Dewey A, Bara A, Lasserson TJ, Walters EH. Colchicine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2003;(4):CD003273.

  22. Dewey A, Bara A, Lasserson TJ, Walters EH. Chloroquine as a steroid sparing agent for asthma. Cochrane Database Syst Rev 2003;(4):DC003275.

  23. Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2008;(3):CD003270.

  24. Corrigan CS. Asthma refractory to glucocorticoids: the role of newer immunosuppressants. Am J Respir Med 2002;1:47-54.

  25. Richeldi L, Ferrara G, Fabbri L, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005;(4):CD002097.

  26. Evans DJ, Cullinan P, Geddes DM, Walters EH, et al. Troleandomycin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002987.

  27. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002985.

  28. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;(2):CD002993.

  29. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;(2):CD000391.

  30. Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis 2008;2(6):409-21.

  31. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004;(3):CD003559.

  32. Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr Opin Pharmacol 2007;7:279-82.

  33. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121(1):5-10.

  34. Holgate ST, Davies DE, Lackie PM, Wilson SJ, et al. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000;105:193-24.



>Revistas >Revista Alergia México >Año2009, No. 4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019